Royal Bank Of Canada Bei Gene, Ltd. Transaction History

Royal Bank Of Canada

$471 Billion
Q3 2024

A detailed history of Royal Bank Of Canada transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Royal Bank Of Canada holds 68,744 shares of BGNE stock, worth $13.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

68,744

Previous 92,927 26.02%

Holding current value

$13.1 Million

Previous $13.3 Million 16.41%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$143.93 - $224.51 $3.48 Million - $5.43 Million	-24,183 Reduced 26.02%	68,744 $15.4 Million
Q2 2024 Aug 14, 2024	BUY	$129.52 - $174.32 $316,287 - $425,689	2,442 Added 2.7%	92,927 $13.3 Million
Q1 2024 Nov 05, 2024	SELL	$141.8 - $181.47 $346,275 - $443,149	-2,442 Reduced 2.63%	90,485 $14.2 Million
Q1 2024 May 15, 2024	BUY	$141.8 - $181.47 $4.85 Million - $6.21 Million	34,233 Added 60.86%	90,485 $14.2 Million
Q4 2023 Feb 14, 2024	SELL	$158.67 - $201.58 $624,049 - $792,814	-3,933 Reduced 6.53%	56,252 $10.1 Million
Q3 2023 Nov 14, 2023	SELL	$179.87 - $225.13 $539,789 - $675,615	-3,001 Reduced 4.75%	60,185 $10.8 Million
Q2 2023 Aug 14, 2023	SELL	$178.3 - $266.78 $1.3 Million - $1.94 Million	-7,290 Reduced 10.34%	63,186 $11.3 Million
Q1 2023 May 15, 2023	BUY	$215.53 - $274.5 $96,126 - $122,427	446 Added 0.64%	70,476 $15.2 Million
Q4 2022 Feb 14, 2023	SELL	$125.51 - $229.3 $215,751 - $394,166	-1,719 Reduced 2.4%	70,030 $15.4 Million
Q3 2022 Nov 14, 2022	SELL	$131.8 - $202.24 $634,353 - $973,381	-4,813 Reduced 6.29%	71,749 $9.67 Million
Q2 2022 Aug 15, 2022	BUY	$121.11 - $216.05 $303,864 - $542,069	2,509 Added 3.39%	76,562 $12.4 Million
Q1 2022 May 16, 2022	BUY	$146.52 - $269.56 $3.52 Million - $6.47 Million	24,020 Added 48.01%	74,053 $14 Million
Q4 2021 Feb 14, 2022	SELL	$248.56 - $389.34 $119,805 - $187,661	-482 Reduced 0.95%	50,033 $13.6 Million
Q3 2021 Nov 15, 2021	BUY	$249.6 - $403.14 $892,320 - $1.44 Million	3,575 Added 7.62%	50,515 $18.3 Million
Q2 2021 Aug 16, 2021	BUY	$292.75 - $367.01 $13.7 Million - $17.2 Million	46,940 New	46,940 $16.1 Million

Others Institutions Holding BGNE

# of Institutions

250

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Account

Royal Bank Of Canada Bei Gene, Ltd. Transaction History